• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains

tetano

Editor, Senior Moderator
Vaccines (Basel). 2019 Sep 18;7(3). pii: E117. doi: 10.3390/vaccines7030117.
[h=1]An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains.[/h] Sun W[SUP]1[/SUP], Zheng A[SUP]2[/SUP], Miller R[SUP]3[/SUP], Krammer F[SUP]4[/SUP], Palese P[SUP]5,[/SUP][SUP]6[/SUP].
[h=3]Author information[/h] 1 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. weina.sun@mssm.edu. 2 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. allen.zheng@icahn.mssm.edu. 3 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. robert.miller@mssm.edu. 4 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. florian.krammer@mssm.edu. 5 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. peter.palese@mssm.edu. 6 Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. peter.palese@mssm.edu.

[h=3]Abstract[/h] Universal influenza virus vaccine candidates that focus on the conserved hemagglutinin (HA) stalk domain and the extracellular domain of the matrix protein 2 (M2e) have been developed to increase the breadth of protection against multiple strains. In this study, we report a novel inactivated influenza virus vaccine approach that combines these two strategies. We inserted a human consensus M2e epitope into the immunodominant antigenic site (Ca2 site) of three different chimeric HAs (cHAs). Sequential immunization with inactivated viruses containing these modified cHAs substantially enhanced M2e antibody responses while simultaneously boosting stalk antibody responses. The combination of additional M2e antibodies with HA stalk antibodies resulted in superior antibody-mediated protection in mice against challenge viruses expressing homologous or heterosubtypic hemagglutinin and neuraminidase compared to vaccination strategies that targeted the HA stalk or M2e epitopes in isolation.


[h=4]KEYWORDS:[/h] ADCC; conserved epitopes; cross-protection; enhanced immunogenicity; immunodominance; universal influenza virus vaccine

PMID: 31540436 DOI: 10.3390/vaccines7030117
Free full text
 
Back
Top Bottom